43.13
-2.27 (-4.99%)
| Penutupan Terdahulu | 45.40 |
| Buka | 45.01 |
| Jumlah Dagangan | 2,389,833 |
| Purata Dagangan (3B) | 1,477,550 |
| Modal Pasaran | 3,874,721,792 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.36 |
| Harga / Jualan (P/S) | 18.15 |
| Harga / Buku (P/B) | 1.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -118.13% |
| Margin Operasi (TTM) | -18,294.02% |
| EPS Cair (TTM) | -2.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.73% |
| Nisbah Semasa (MRQ) | 21.64 |
| Aliran Tunai Operasi (OCF TTM) | -188.82 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -118.57 M |
| Pulangan Atas Aset (ROA TTM) | -9.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.07% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CRISPR Therapeutics AG | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.69% |
| % Dimiliki oleh Institusi | 83.82% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 94.00 (Chardan Capital, 117.92%) | Beli |
| Median | 84.00 (94.74%) | |
| Rendah | 53.00 (RBC Capital, 22.87%) | Pegang |
| Purata | 74.40 (72.48%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 48.16 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 20 Dec 2024 | 86.00 (99.37%) | Beli | 39.95 |
| Chardan Capital | 10 Dec 2024 | 94.00 (117.92%) | Beli | 48.68 |
| Barclays | 06 Nov 2024 | 55.00 (27.51%) | Pegang | 50.72 |
| Needham | 06 Nov 2024 | 84.00 (94.74%) | Beli | 50.72 |
| RBC Capital | 06 Nov 2024 | 53.00 (22.87%) | Pegang | 50.72 |
| 04 Oct 2024 | 53.00 (22.87%) | Pegang | 45.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Dec 2024 | Pengumuman | CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting |
| 14 Nov 2024 | Pengumuman | CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference |
| 07 Nov 2024 | Pengumuman | CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference |
| 05 Nov 2024 | Pengumuman | CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |